FindTrial
Sign In

Sandostatin

DRUG5 trials

Sponsors

Department of Urology, School of Medicine, Kyorin University, Stanford University, University of California, San Francisco, Ginkgo Leaf Center for Rare Disorders, Cliniques universitaires Saint-Luc- Université Catholique de Louvain

Conditions

AcromegalyAutosomal Dominant Polycystic Kidney Disease (ADPKD), Autosomal Dominant Polycystic Liver Disease (ADPLD).Breast CancerCarcinoid SyndromeNeuroendocrine TumorsProstate Cancer

Phase 2

Sandostatin for Patients With Androgen Independent Prostate Cancer
TerminatedNCT00510224
University of California, San FranciscoProstate Cancer
Start: 2007-07-31End: 2009-08-31Updated: 2013-12-11
Somatostatin (Sandostatin) Safety Study on Polycystic Kidney and Liver Disease: Phase II study
Active, not recruitingJPRN-UMIN000009214
Department of Urology, School of Medicine, Kyorin UniversityAutosomal Dominant Polycystic Kidney Disease (ADPKD), Autosomal Dominant Polycystic Liver Disease (ADPLD).
Start: 2012-12-15Target: 4Updated: 2026-06-29

Phase 4

Sandostatin (Octreotide LAR) May Lead to Clinical Improvement Through Receptor Occupation Optimisation
TerminatedNCT04140409
Cliniques universitaires Saint-Luc- Université Catholique de LouvainCarcinoid Syndrome, Neuroendocrine Tumors
Start: 2016-02-02End: 2019-09-19Updated: 2019-10-25

Unknown Phase

Stress, Diurnal Cortisol, and Breast Cancer Survival
CompletedNCT00226967
Stanford UniversityBreast Cancer
Start: 2002-09-08End: 2005-12-31Target: 115Updated: 2020-01-27
The Longitudinal Approach to Acromegaly: A Pattern of Treatment and Comparative Effectiveness Research
RecruitingNCT03158090
Ginkgo Leaf Center for Rare DisordersAcromegaly
Start: 2017-12-15End: 2051-01-30Target: 1965Updated: 2022-03-16

Related Papers

Safety study of somatostatin analogue octreotide for autosomal dominant polycystic kidney disease in Japan.
2014-10-294 citations